

days postoperatively (fig. 1) was interpreted as showing part of the stethoscope in the duodenum, later review of the film, together with the location of the stethoscope at gastroscopy, indicated it never left the stomach. Thus, we would recommend elective removal of an errant esophageal stethoscope with an endoscope upon recognition of the problem, rather than nonintervention in the hope of spontaneous distal passage.

In summary, we report a case of inadvertent passage of an esophageal stethoscope into the stomach of an anesthetized patient. Diagnosis was delayed until the sixth postoperative day and was aided by the characteristic "booster rocket" silhouette of the proximal end of the esophageal stethoscope (fig. 1). Removal was accomplished without difficulty 5½ weeks after insertion of the stethoscope. Elective removal, rather than expectant

hope for passage of an esophageal stethoscope located in the stomach, is recommended.

REFERENCES

1. Mitchell SA, Shoultz DL, Herren AL, Benumof JL: Deglutition of an endotracheal tube: Case report. *Anesth Analg* 57:590-591, 1978
2. Hoffman S, Jedeikin R: Swallowed endotracheal tube in an adult. *Anesth Analg* 63:457-459, 1984
3. Seebacher J, Nozik D, Mathieu A: Inadvertent intracranial introduction of a nasogastric tube, a complication of severe maxillofacial trauma. *ANESTHESIOLOGY* 42:100-102, 1975
4. Borovich B, Braun J, Yosefovich T, Guilburd JN, Grushkiewicz J, Peyser E: Intracranial penetration of nasogastric tube. *Neurosurgery* 8:245-247, 1981
5. Sweatman AJ, Tomasello PA, Loughhead MG, Orr M, Datta T: Misplacement of nasogastric tubes and esophageal monitoring devices. *Br J Anaesth* 50:389-392, 1978

Anesthesiology
62:645-646, 1985

Atracurium: Hypotension, Tachycardia and Bronchospasm

JANET N. SILER, M.D.,* JOHN G. MAGER, JR.,† M.D., MELVILLE Q. WYCHE, JR., M.D.‡

Histamine release following iv administration of atracurium can cause hypotension and tachycardia.¹ We describe such a case where significant tachycardia, hypotension, and bronchospasm occurred following an iv bolus of atracurium.

REPORT OF A CASE

A 34-year-old, 48-kg, ASA physical status I woman was scheduled for laparoscopy, lysis of adhesions, and possible laparotomy for infertility. She gave a negative history for drug allergies. Following premedication with hydrocortisone 100 mg, morphine sulfate 8 mg and glycopyrrolate 0.4 mg im, she received fentanyl 100 µg and diazepam 5 mg iv prior to induction of anesthesia with thiopental 425 mg iv following which BP was 110/80 mmHg, heart rate 100 bpm with controlled respirations via face mask. Atracurium 30 mg

iv was administered prior to tracheal intubation. Less than 30 s later, heart rate increased from 100 to 150 bpm, systolic BP decreased from 110 to 55 mmHg, and ventilation via face mask became difficult. The ECG monitor showed a supraventricular tachycardia. Skin flushing was not observed. Carotid massage, edrophonium 10 mg, and methoxamine 6 mg in divided doses iv were without effect. Her trachea was intubated easily and auscultation of her lungs revealed inspiratory and expiratory wheezing bilaterally. The systolic BP was now 60 mmHg and heart rate 150 bpm. One hundred per cent oxygen was given and the rate of iv fluids increased. An iv neosynephrine drip 40 µg/ml to a total of 400 µg was given, resulting eventually in a BP of 110/50 mmHg and heart rate of 110 bpm. At this time, pH_a was 7.31, Pa_{O_2} 485 mmHg, Pa_{CO_2} 47 mmHg, and HCO_3^- 23.2 mEq/l. The return of her cardiovascular variables toward preatracurium values occurred 20 minutes following iv atracurium. At this time, the bronchospasm resolved spontaneously and the neosynephrine was discontinued. It was decided to proceed with the planned surgical procedure.

During the 2-h operation, anesthesia was maintained with enflurane, N_2O , O_2 , and intermittent iv injections of pancuronium totaling 3 mg. At the end of surgery, muscular blockade was reversed without incident, following the administration of neostigmine 4 mg and glycopyrrolate 0.4 mg iv while monitoring neuromuscular activity with a nerve stimulator. Her recovery room and postoperative courses were unremarkable.

DISCUSSION

This patient's initial increase in heart rate was interpreted as a spontaneous supraventricular tachycardia (SVT). It was treated with carotid massage and iv edrophonium. When the systolic BP of 55 mmHg was noted, methoxamine and neosynephrine were administered iv. The appearance of bronchospasm suggested

* Assistant Professor, Department of Anesthesia, University of Pennsylvania, School of Medicine at Pennsylvania Hospital.

† Resident, Department of Anesthesia, University of Pennsylvania, School of Medicine.

‡ Associate Professor, Department of Anesthesia, University of Pennsylvania, School of Medicine, Director, Department of Anesthesiology, Pennsylvania Hospital.

Received from the Department of Anesthesia, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, and the Department of Anesthesia, Pennsylvania Hospital, Philadelphia, Pennsylvania. Accepted for publication November 16, 1984.

Address reprint requests to Dr. Siler: Department of Anesthesiology, Pennsylvania Hospital, CORE Basement, Eighth and Spruce Streets, Philadelphia, Pennsylvania 19107.

Key words: Neuromuscular relaxants: atracurium; histamine. Complications, hypotension.

an etiology other than SVT, and the possibility of histamine release was entertained even though cutaneous flushing was not observed. The BP started to increase, and further drug therapy did not appear to be indicated. Bronchospasm resolved spontaneously.

Significant cardiovascular changes following the iv atracurium injection at doses of 0.5–0.6 mg/kg have been reported. These consisted of decreases in arterial blood pressure to 86.7% and 79.5% of control and heart rate increases to 105.5% and 108.3% of control.¹ The changes in arterial BP and heart rate disappeared within 5 min and usually were associated with flushing of the face, suggesting the possibility of histamine release. In a study with contrasting results, Payne and Hughes² found no significant cardiovascular changes at doses up to 0.6 mg/kg. The speed of injection may be important in explaining these dissimilar results.³ In our patient, a dose of 0.6 mg/kg was administered over a period of approximately 5 s. The patient's body weight preoperatively was estimated to be higher than her actual weight as recorded on her hospital chart. No attempt was made to modify the speed of the atracurium injection.

The atracurium package insert recommends 0.5 mg/kg to be the maximum dose for tracheal intubation. With a higher dose as used in this patient, the release of histamine would not have been unexpected, retrospectively. However, the return of her cardiovascular variables toward normal should have occurred within a 5-min time period.

Histamine is a naturally occurring vasoactive amine with varying distribution from tissue to tissue within the human body. Among its pharmacologic actions are an increase in myocardial contractility and automaticity. Peripherally, histamine acts as a potent vasodilator. Thus, hypotension occurs, as does tachycardia, either as a reflex effect related to the hypotension or a direct effect, depending on the plasma histamine level. Dilatation of cutaneous blood vessels with increased microvascular permeability results in flushing of the skin and increases in skin temperature. Stimulation of bronchial musculature results in bronchoconstriction. All of these effects are dependent on plasma histamine levels.⁴

Following the administration of clinical doses of some neuromuscular blocking drugs, histamine may be released in quantities sufficient to increase circulating plasma histamine.^{5,6} These drugs include *d*-tubocurarine, succinyl-choline, gallamine, decamethonium, alcuronium, pancuronium, and atracurium.^{5–7}

In our patient the tachycardia, hypotension, and bronchospasm may be explained by the actions of histamine. Of concern is the length of time that elapsed before the return to induction levels of BP, heart rate, and the resolution of wheezing. The use of edrophonium and methoxamine to treat the initially perceived supra-

ventricular tachycardia with hypotension were without effective cardiovascular response. However, neither of these agents are specific H₁ or H₂ histamine receptor antagonists. Simultaneous blocking of H₁ and H₂ histamine receptors can counteract the vasodilator response to histamine in forearm blood flow in humans.⁸ In subsequent animal studies, H₁-receptor antagonists block the immediate response and H₂-receptor antagonists block the sustained response to histamine.⁹

Was the response of this patient to atracurium an anaphylactic or anaphylactoid reaction? An anaphylactic reaction is associated with antibody formation or activation of the complement system by an alternate pathway. An anaphylactoid reaction does not involve antibodies. However, we did not obtain plasma histamine levels or subsequent IgE or IgG antibody levels. There was no previous history of exposure to atracurium. If there is an associated reagin that can occur or was triggered to form an antigen by atracurium, it is not presently known.

In summary, this case demonstrates significant tachycardia, hypotension, and bronchospasm following a large intubation dose of atracurium. The presently proposed mechanisms for this response include histamine release and/or a possible allergic reaction (anaphylactoid *vs.* anaphylaxis).

REFERENCES

1. Basta SJ, Ali HH, Savarese JJ, Sunder N, Gionfriddo M, Cloutier G, Lineberry C, Cato AE: Clinical pharmacology of atracurium besylate (BW 33A): A new non-depolarizing muscle relaxant. *Anesth Analg* 61:723–729, 1982
2. Payne JP, Hughes R: Evaluation of atracurium in anaesthetized man. *Br J Anaesth* 53:45–54, 1981
3. Scott RPF, Savarese JJ, Ali HH, Gargarian M, Basta SJ, Sunder N, Gionfriddo BS, Baston AG: Atracurium: Clinical strategies for preventing histamine release and attenuating the hemodynamic response (Abstract). *ANESTHESIOLOGY* 61(Suppl): 287, 1984
4. Owen DAA: Physiology and pharmacology of histamine: Cardiovascular studies in man, *Clinics in Anaesthesiology*. Edited by Moss J. Philadelphia, WB Saunders, 1984, pp 383–401
5. Lorenz W, Roher HD, Doenicke A, Ohmann CH: Histamine release in anaesthesia and surgery: A new method to evaluate its clinical significance with several types of casual relationship, *Clinics in Anaesthesiology*. Edited by Moss J. Philadelphia, WB Saunders, 1984, pp 403–426
6. Stoelting RK: Allergic reactions during anesthesia. *Anesth Analg* 62:341–356, 1983
7. Basta SJ, Savarese JJ, Ali HH, Moss J, Gionfriddo M: Histamine-releasing potencies of atracurium, dimethyl tubocurarine and tubocurarine. *Br J Anaesth* 55:105–106S, 1983
8. Chipman P, Glover WE: Histamine H₂-receptors in the human peripheral circulation. *Br J Pharmacol* 56:494–496, 1976
9. Levi R, Owen DAA, Trzeciakowski J: Actions of histamine on the heart and vasculature, *Pharmacology of Histamine Receptors*. Edited by Ganellin CR, Parsons ME. Boston, PSG Wright, 1982, pp 236–297